Teva Reports Mixed Q2 Results, Shares Rise on Revenue Beat and Branded Drug Growth
Teva Pharmaceutical Industries (NYSE:TEVA) reported second-quarter results that were mixed but well received by investors. While the company missed adjusted earnings expectations due to acquisition-related costs, revenue beat forecasts at $4.14 billion—up slightly from last year—and strong performance in its branded drug portfolio drove a 3% rise in shares. The shortfall in earnings was attributed primarily to expenses related to Teva's recent acquisition of Emalex Biosciences and the associated therapy ecopipam, which reduced quarterly earnings by $0.61 per share. Despite this, three key branded medicines—AUSTEDO, AJOVY, and UZEDY—generated over $1 billion in combined revenue during the quarter with double-digit growth rates. Teva raised its full-year revenue guidance to between $16.5 billion and $16.85 billion and increased expectations for annual sales of these three products to approximately $3.7 billion, reflecting continued confidence in their performance.
Tickers: $TEVA